Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medivir reports additional positive Phase IIb interim results with Hep C compound

This article was originally published in Scrip

Executive Summary

Medivir is building up a strong body of data to support its investigational once-daily oral protease inhibitor, TMC435, for treating hepatitis C, with which to challenge the two current leaders in the field, boceprevir and telaprevir. It has reported further positive interim results from a Phase IIb of the drug in treatment-naïve patients with hepatitis C virus genotype-1.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts